Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lexaptepid pegol
- Development stage
- Phase 2
- Lead developer
- TME Pharma
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Lexaptepid pegol (NOX-H94) is a pegylated Spiegelmer (an L-enantiomer RNA aptamer) that acts as a high-affinity antagonist of hepcidin. Developed by TME Pharma (formerly NOXXON Pharma), it is designed to treat anemia of chronic disease (ACD) and functional iron deficiency, particularly in patients who are hyporesponsive to erythropoiesis-stimulating agents (ESAs). Hepcidin is a key regulatory hormone that inhibits iron absorption and recycling by binding to ferroportin; by neutralizing hepcidin, lexaptepid pegol increases iron availability for erythropoiesis. The drug has been investigated in clinical trials for patients with dialysis-dependent chronic kidney disease, multiple myeloma, and lymphoma.
- Other names
- lexaptepid
02
Targets
HAMP (Hepcidin)
Beyond the preview
Go deeper on lexaptepid pegol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lexaptepid pegol.